5593-20-4

• 常用中文名：17,21-二丙酸倍他米松酯
• 常用英文名：Betamethasone Dipropionate
• CAS号：5593-20-4
• 分子式：C₂₈H₃₇FO₇
• 分子量：504.588
• 相关类别： 原料药 激素及调节内分泌功能类药 肾上腺皮质激素类药
• 发布时间：2018-09-30 13:28:25
• 更新时间：2026-07-03 19:12:06
• Betamethasone dipropionate 是一种糖皮质激素类固醇,具有抗炎和免疫抑制能力。

名称

• 中文名: 倍他米松二丙酸酯
• 英文名: betamethasone dipropionate
• 中文别名: Betamethasone dipropionate 10mM * 1mL in DMSO试剂; 二丙酸倍他米松 标准品; 二丙酸倍他米松峰鉴别 标准品; 丙酸倍他米松 标准品; 倍他米松二丙酸酯|Betamethasone-17,21-dipropionate; 化合物:Betamethasone Dipropionate; 倍他米松双丙酸酯; 2H5]-倍他米松-17,21-二丙酸酯; BETAMETHASONE DIPROPIONATE 标准品; 9α-氟-11β,17α,21-三羟基-16β-甲基-1,4-孕甾-3,20-二酮-17,21-二丙酸酯; 二丙酸倍他米松,10 MM DMSO 溶液; 倍他米松二丙酸脂; 二丙酸信他米松; 二丙酸倍他米松杂质; 甲醇中倍他米松双丙酸酯(二丙酸倍他米松酯)溶液标准物质; 属头孢菌类抗生素; 乙腈中倍他米松双丙酸酯溶液, 100ΜG/ML; 倍他米松丙二酸酯; 倍他米松丙酸酯; 倍他米松二丙酸酯启步科技; 化合物：Betamethasone Dipropionate; 倍他米松二丙酸酯(倍他米松双丙酸酯)检测标准品; 二丙酸倍他米松酯; 二丙酸倍他米松/二丙酸倍他咪松; DIPROLENE AF|||SCH 11460|||二丙酸倍他米松|||BETAMETHASONE 17,21-DIPROPIONATE|||DIPROLENE|||倍他米松二丙酸酯|||DIPROSONE; 二丙酸倍他咪松; 17,21-二丙酸倍他米松; 倍他米松二丙酸酯 标准品; (8S,9R,10S,11S,13S,14S,16S,17R)-9-氟-11-羟基-10,13,16-三甲基-3-氧代-17-(2-(丙酰氧基)乙酰基)-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷并[A]菲-17-基 丙酸酯; 二丙酸倍他米松BETAMETHASONE DIPROPIONATE; 倍他米松二丙酸酯/9Α-氟-11Β,17Α,21-三羟基-16Β-甲基-1,4-孕甾-3,20-二酮-17,21-二丙酸酯/倍他米松17,21-二丙酸酯; 倍他米松二丙酸酯/A1A; 乙腈中倍他米松二丙酸酯; 9Α-氟-11Β,17Α,21-三羟基-16Β-甲基-1,4-孕甾-3,20-二酮-17,21-二丙酸酯; 倍他米松17,21-二丙酸酯; 丙酸倍他米松; 倍他米松双丙酸酯溶液,100PPM
• 英文别名: (11-beta,16-beta)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate; 17,21 betaMethasone dipropionate ester; Psorion; EINECS 227-005-2; propanoic acid [2-[(8R,9S,10R,11S,13S,14R,16S,17R)-8-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(1-oxopropoxy)-6,7,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] ester; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione 17,21-Dipropionate; β-Methasone 17,21-dipropionate; Betamethasone 17,21-dipropionat; Pregna-1,4-diene-3,20-dione,9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11b,16b); Betamethasone 17,21-dipropionate; Betamethasone dipropionate solution in Acetonitrile, 100μg/mL; BETAMETHASONEDIPROPIONATE,MICRONIZEDPOWDER; Rinderon DP; Diprolene AF; 9ALPHA-FLUORO-16BETA-METHYL-11BETA,17ALPHA,21-TRIHYDROXY-1,4-PREGNADIENE-3,20-DIONE 17,21-DIPROPIONATE; BETANMETHASONE DIPROPIONATE; Betamethasone dipropionate CRS; diproderm; Betamethasone 17,21-dipropionate //BP; Diprosis; Betanmethasone Dipronate; diprosis; Rinderon-DP; 9-Fluoro-16-methyl-11,17,21-trihydroxy-1,4-pregnadiene-3,20-dione17,21-dipropionate; Betamethasone17,21-dipropionate; diprosone; (11b,16b)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21-Dipropionate; BETAMETHASONE DIPROPIONATE; Betamethasone dipropionate for system suitability A; Betamethasonediproprionate; Betamethasone dipropionate for peak identification CRS; Betamethasone dipropionate; BetaMethasone dipropionat; S 3440; Maxivate; BETAMETHASONE 17,21-DI-PROPIONATE; propionic acid [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-3-keto-10,13,16-trimethyl-17-(2-propionyloxyacetyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester; High Purity Raw Powder Betamethason 17, 21-Dipropionate; Betamethasone 17,21; Diprolene; Pregna-1,4-diene-3,20-dione, 9-fluoro-11β,17,21-trihydroxy-16β-methyl-, 17,21-dipropionate (7CI, 8CI); UNII-826Y60901U; Betamethasone 17; Anhydrous Beclometasone Dipropionate; Betamethasone dipropionate for system suitability; Betamethaasone Dipropionate; (11β,16β)-9-Fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate; SCH-11460; [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-propanoyloxyacetyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-propanoyloxyethanoyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; Betamethasone dipropionate for peak identification (Y0001416); Betamethasone 17,21-dipropionate(5-4); 17,21-Di(propionyloxy)-9-fluoro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione; 9a-fluoro-16b-methyl-11b,17a,21-trihydroxy-1,4-pregnadiene-3,20-dione 17,21-dipropionate; Betamethasone dipropionate (B1040000)Q: What is Betamethasone dipropionate (B1040000) Q: What is the CAS Number of Betamethasone dipropionate (B1040000); (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-(propionyloxy)acetyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate; diprolene; Diprophos; Pregna-1,4-Diene-3,20-Dione,9-Fluoro-11-Hydroxy-16-Methyl-17,21-Bis(1-Oxopropoxy)-,(11Beta,16Beta); (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-[(propanoyloxy)acetyl]-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propanoate; Diprosone; Betamethasone 17,21-dipropionate,9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17,21-dipropionate; betamethasone-17,21-dipropionate; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11β,16β); Diproderm; MFCD00133140; Sch; 1,4-PREGNADIEN-9-ALPHA-FLUORO-16-BETA-METHYL-11-BETA, 17,21-TRIOL-3,20-DIONE 17,21-DIPROPIONATE; Betamethasone dipropionate for peak identification; Betamethasone 17,21-Dipropionate >; BETAMETHASONE 17-ALPHA,21-DIPROPIONATE; 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-di(propionate)

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 603.2±55.0 °C at 760 mmHg
• 熔点: 178 °C
• 分子式: C₂₈H₃₇FO₇
• 分子量: 504.588
• 闪点: 318.6±31.5 °C
• 精确质量: 504.252319
• PSA: 106.97000
• LogP: 4.42
• 外观性状: 固体;White to Light yellow powder to crystal
• 蒸汽压: 0.0±3.9 mmHg at 25°C
• 折射率: 1.550
• 储存条件:

  常温，避光，阴凉干燥处，密封保存

• 稳定性:

  常温常压下稳定

• 分子结构:

  1、 摩尔折射率：128.66

  2、 摩尔体积（m³/mol）：403.9

  3、 等张比容（90.2K）：1069.7

  4、 表面张力（dyne/cm）：49.1

  5、 极化率（10 ^-24cm ³）：51.00

• 计算化学:

  1、 疏水参数计算参考值（XlogP）：3.6

  2、 氢键供体数量：1

  3、 氢键受体数量：8

  4、 可旋转化学键数量：8

  5、 互变异构体数量：6

  6、 拓扑分子极性表面积（TPSA）：107

  7、 重原子数量：36

  8、 表面电荷：0

  9、 复杂度：1050

  10、 同位素原子数量：0

  11、 确定原子立构中心数量：8

  12、 不确定原子立构中心数量：0

  13、 确定化学键立构中心数量：0

  14、 不确定化学键立构中心数量：0

  15、 共价键单元数量：1

• 更多:

  1. 性状：未确定

  2. 密度（g/mL,25/4℃）：未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：178

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC,5.2kPa）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：69

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kPa,25ºC）：未确定

  12. 饱和蒸气压（kPa,60ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：未确定

生物活性

• 描述: Betamethasone dipropionate 是一种糖皮质激素类固醇,具有抗炎和免疫抑制能力。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 糖皮质激素受体
  研究领域 >> 炎症/免疫
  天然产物 >> 其他
• 靶点:

  Glucocorticoid Receptor

• 体内研究: 倍他米松二丙酸酯是一种超高效皮质类固醇,用于治疗炎症性皮肤病,如皮炎,湿疹和牛皮癣。它是肾上腺皮质类固醇的合成类似物。

MSDS

17,21-二丙酸倍他米松酯 修改号码：5 模块1. 化学品 产品名称： Betamethasone 17,21-Dipropionate 修改号码： 5 模块2. 危险性概述 GHS分类 　物理性危害未分类 　健康危害未分类 　环境危害未分类 GHS标签元素 　图标或危害标志无 　信号词无信号词 　危险描述无 　防范说明无 模块3. 成分/组成信息 单一物质/混和物单一物质 化学名(中文名)： 17,21-二丙酸倍他米松酯 百分比： >97.0%(LC) CAS编码： 5593-20-4 俗名： 9α-Fluoro-11β,17α,21-trihydroxy-16β-methyl-1,4-pregnadiene-3,20-dione 17,21-Dipropionate 分子式： C28H37FO7 模块4. 急救措施 吸入： 将受害者移到新鲜空气处，保持呼吸通畅，休息。若感不适请求医/就诊。 皮肤接触： 立即去除/脱掉所有被污染的衣物。用水清洗皮肤/淋浴。 若皮肤刺激或发生皮疹：求医/就诊。 眼睛接触：用水小心清洗几分钟。如果方便，易操作，摘除隐形眼镜。继续清洗。 如果眼睛刺激：求医/就诊。 食入： 若感不适，求医/就诊。漱口。 紧急救助者的防护：救援者需要穿戴个人防护用品，比如橡胶手套和气密性护目镜。 模块5. 消防措施 合适的灭火剂：干粉，泡沫，雾状水，二氧化碳 17,21-二丙酸倍他米松酯 修改号码：5 模块5. 消防措施 特殊危险性：小心，燃烧或高温下可能分解产生毒烟。 特定方法：从上风处灭火，根据周围环境选择合适的灭火方法。 非相关人员应该撤离至安全地方。 周围一旦着火：如果安全，移去可移动容器。 消防员的特殊防护用具：灭火时，一定要穿戴个人防护用品。 模块6. 泄漏应急处理 个人防护措施，防护用具， 使用个人防护用品。远离溢出物/泄露处并处在上风处。 紧急措施：泄露区应该用安全带等圈起来，控制非相关人员进入。 环保措施：防止进入下水道。 控制和清洗的方法和材料：清扫收集粉尘，封入密闭容器。注意切勿分散。附着物或收集物应该立即根据合适的 法律法规处置。 模块7. 操作处置与储存 处理 技术措施：在通风良好处进行处理。穿戴合适的防护用具。防止粉尘扩散。处理后彻底清洗双手 和脸。 注意事项：如果粉尘或浮质产生，使用局部排气。 操作处置注意事项：避免接触皮肤、眼睛和衣物。 贮存 储存条件：保持容器密闭。存放于凉爽、阴暗处。 远离不相容的材料比如氧化剂存放。 包装材料：依据法律。 模块8. 接触控制和个体防护 工程控制：尽可能安装封闭体系或局部排风系统，操作人员切勿直接接触。同时安装淋浴器和洗 眼器。 个人防护用品 　呼吸系统防护：防尘面具。依据当地和政府法规。 　手部防护：防护手套。 　眼睛防护：安全防护镜。如果情况需要，佩戴面具。 　皮肤和身体防护：防护服。如果情况需要，穿戴防护靴。 模块9. 理化特性 固体 外形（20°C）： 外观： 晶体-粉末 颜色： 白色-微浅黄色 气味：无资料 pH:无数据资料 熔点： 178°C 沸点/沸程无资料 闪点：无资料 爆炸特性 　爆炸下限：无资料 　爆炸上限：无资料 密度：无资料 溶解度： [水]无资料 [其他溶剂]无资料 17,21-二丙酸倍他米松酯 修改号码：5 模块10. 稳定性和反应性 化学稳定性：一般情况下稳定。 危险反应的可能性：未报道特殊反应性。 须避免接触的物质氧化剂 危险的分解产物: 一氧化碳, 二氧化碳, 氟化氢 模块11. 毒理学信息 急性毒性： orl-mus LD50:>5000 mg/kg orl-rat LD50:>4000 mg/kg scu-mus LD50:78100 ug/kg ipr-rat LD50:4000 mg/kg ipr-mus LD50:103 mg/kg 对皮肤腐蚀或刺激：无资料 对眼睛严重损害或刺激：无资料 生殖细胞变异原性：无资料 致癌性： IARC =无资料 NTP =无资料 生殖毒性：无资料 RTECS 号码: TU4058000 模块12. 生态学信息 生态毒性： 鱼类：无资料 甲壳类：无资料 藻类：无资料 残留性 / 降解性：无资料 潜在生物累积 （BCF):无资料 土壤中移动性 　log水分配系数：无资料 　土壤吸收系数 （Koc）：无资料 　亨利定律无资料 constant(PaM3/mol): 模块13. 废弃处置 如果可能，回收处理。请咨询当地管理部门。建议在可燃溶剂中溶解混合，在装有后燃和洗涤装置的化学焚烧炉中 焚烧。废弃处置时请遵守国家、地区和当地的所有法规。 模块14. 运输信息 联合国分类：与联合国分类标准不一致 UN编号：未列明 模块15. 法规信息 《危险化学品安全管理条例》（2002年1月26日国务院发布，2011年2月16日修订）: 针对危险化学品的安全使用、 生产、储存、运输、装卸等方面均作了相应的规定。 17,21-二丙酸倍他米松酯 修改号码：5 模块16 - 其他信息 N/A

毒性和生态

生态学数据: 可燃; 燃烧产生有毒氟化物烟雾 CHEMICAL IDENTIFICATION RTECS NUMBER : TU4058000 CHEMICAL NAME : Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-, 17,21-dipropionate CAS REGISTRY NUMBER : 5593-20-4 LAST UPDATED : 199712 DATA ITEMS CITED : 23 MOLECULAR FORMULA : C28-H37-F-O7 MOLECULAR WEIGHT : 504.65 WISWESSER LINE NOTATION : L E5 B666 OV AHTTT&J A1 BF CQ E1 FV1OV2 FOV2 G1 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : SKIZAB Shikoku Igaku Zasshi. Shikoku Medical Journal. (Tokushima Igakkai, Tokushima Daigaku Igakubu, Kuramoto-cho, Tokushima 770, Japan) V.1- 1950- Volume(issue)/page/year: 29,153,1973 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : SKIZAB Shikoku Igaku Zasshi. Shikoku Medical Journal. (Tokushima Igakkai, Tokushima Daigaku Igakubu, Kuramoto-cho, Tokushima 770, Japan) V.1- 1950- Volume(issue)/page/year: 29,153,1973 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : SKIZAB Shikoku Igaku Zasshi. Shikoku Medical Journal. (Tokushima Igakkai, Tokushima Daigaku Igakubu, Kuramoto-cho, Tokushima 770, Japan) V.1- 1950- Volume(issue)/page/year: 29,153,1973 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Behavioral - antipsychotic Skin and Appendages - hair REFERENCE : SKIZAB Shikoku Igaku Zasshi. Shikoku Medical Journal. (Tokushima Igakkai, Tokushima Daigaku Igakubu, Kuramoto-cho, Tokushima 770, Japan) V.1- 1950- Volume(issue)/page/year: 29,153,1973 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 103 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,753,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 78100 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,753,1982 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Administration onto the skin SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 58240 ug/kg/13W-I TOXIC EFFECTS : Endocrine - changes in spleen weight Blood - changes in erythrocyte (RBC) count Nutritional and Gross Metabolic - weight loss or decreased weight gain REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 27,4013,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 15600 ug/kg/26W-I TOXIC EFFECTS : Endocrine - changes in spleen weight Blood - changes in erythrocyte (RBC) count Blood - changes in leukocyte (WBC) count REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 18,507,1979 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 910 ug/kg SEX/DURATION : male 26 week(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 18,507,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 30 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 8,705,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 7500 ug/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 8,705,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 120 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 8,705,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 480 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 8,705,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 936 ug/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 8,705,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 3750 ug/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Effects on Embryo or Fetus - other effects to embryo REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 8,705,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 640 ug/kg SEX/DURATION : female 12 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 21,645,1981 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 120 ug/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 8,705,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 10 ug/kg SEX/DURATION : female 24 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - endocrine system REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 11,1672,1977 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 6 ug/kg SEX/DURATION : female 15 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 21,645,1981 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 12 ug/kg SEX/DURATION : female 15 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 21,645,1981 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 130 ug/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 11,1672,1977 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 32500 ng/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 11,1672,1977 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X1524 No. of Facilities: 93 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 8033 (estimated) No. of Female Employees: 7423 (estimated)

安全

• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危害码 (欧洲): Xi
• 安全声明 (欧洲): S22-S24/25
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 2
• RTECS号: TU4058000

上下游产品

上游产品  0
下游产品  4
378-44-9 5534-13-4 24703-00-2 78144-00-0